246 related articles for article (PubMed ID: 25445000)
1. An analysis of legal warnings after drug approval in Thailand.
Sriphiromya P; Theeraroungchaisri A
Regul Toxicol Pharmacol; 2015 Feb; 71(1):108-13. PubMed ID: 25445000
[TBL] [Abstract][Full Text] [Related]
2. Review of FDA Amendments Act Section 921 Experience in Posting Data-mining Results from the FAERS Database.
Beninger P; Murray M
Clin Ther; 2021 Feb; 43(2):380-395. PubMed ID: 33504449
[TBL] [Abstract][Full Text] [Related]
3. Impact of United States Food and Drug Administration's boxed warnings on adverse drug reactions reporting rates and risk mitigation for multiple myeloma drugs.
Garg V; Raisch DW; McKoy JM; Trifilio SM; Holbrook J; Edwards BJ; Belknap SM; Samaras AT; Nardone B; West DP
Expert Opin Drug Saf; 2013 May; 12(3):299-307. PubMed ID: 23480866
[TBL] [Abstract][Full Text] [Related]
4. Trends in boxed warnings and withdrawals for novel therapeutic drugs, 1996 through 2012.
Cheng CM; Shin J; Guglielmo BJ
JAMA Intern Med; 2014 Oct; 174(10):1704-5. PubMed ID: 25127107
[No Abstract] [Full Text] [Related]
5. New and incremental FDA black box warnings from 2008 to 2015.
Solotke MT; Dhruva SS; Downing NS; Shah ND; Ross JS
Expert Opin Drug Saf; 2018 Feb; 17(2):117-123. PubMed ID: 29215916
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of Pre-marketing Factors to Predict Post-marketing Boxed Warnings and Safety Withdrawals.
Schick A; Miller KL; Lanthier M; Dal Pan G; Nardinelli C
Drug Saf; 2017 Jun; 40(6):497-503. PubMed ID: 28342075
[TBL] [Abstract][Full Text] [Related]
7. FDA boxed warnings: how to prescribe drugs safely.
O'Connor NR
Am Fam Physician; 2010 Feb; 81(3):298-303. PubMed ID: 20112888
[TBL] [Abstract][Full Text] [Related]
8. Ethical and Practical Considerations in Removing Black Box Warnings from Drug Labels.
Yeh JS; Sarpatwari A; Kesselheim AS
Drug Saf; 2016 Aug; 39(8):709-14. PubMed ID: 27000800
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
[TBL] [Abstract][Full Text] [Related]
10. Timing of new black box warnings and withdrawals for prescription medications.
Lasser KE; Allen PD; Woolhandler SJ; Himmelstein DU; Wolfe SM; Bor DH
JAMA; 2002 May; 287(17):2215-20. PubMed ID: 11980521
[TBL] [Abstract][Full Text] [Related]
11. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
Murphy S; Roberts R
J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
[TBL] [Abstract][Full Text] [Related]
12. New drugs: watch out for unexpected adverse effects.
Prescrire Int; 2002 Oct; 11(61):150-1. PubMed ID: 12378747
[TBL] [Abstract][Full Text] [Related]
13. Differences between the United States and Japan in labels of oncological drugs.
Jayaputra K; Ono S
Pharmacoepidemiol Drug Saf; 2017 Feb; 26(2):143-151. PubMed ID: 27670850
[TBL] [Abstract][Full Text] [Related]
14. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
Wysowski DK; Swartz L
Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
[TBL] [Abstract][Full Text] [Related]
15. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
Mostaghim SR; Gagne JJ; Kesselheim AS
BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
[No Abstract] [Full Text] [Related]
16. Pharmacovigilance and post-black market surveillance.
Langlitz N
Soc Stud Sci; 2009 Jun; 39(3):395-420. PubMed ID: 19848184
[TBL] [Abstract][Full Text] [Related]
17. Sources of Evidence Triggering and Supporting Safety-Related Labeling Changes: A 10-Year Longitudinal Assessment of 22 New Molecular Entities Approved in 2008 by the US Food and Drug Administration.
Croteau D; Pinnow E; Wu E; Muñoz M; Bulatao I; Dal Pan G
Drug Saf; 2022 Feb; 45(2):169-180. PubMed ID: 35113347
[TBL] [Abstract][Full Text] [Related]
18. Drug-induced ocular adverse reactions: review of the safety alerts issued during the last decade.
Penedones A; Mendes D; Alves C; Marques FB
J Ocul Pharmacol Ther; 2015 Jun; 31(5):258-68. PubMed ID: 25871404
[TBL] [Abstract][Full Text] [Related]
19. Postmarketing safety of orphan drugs: a longitudinal analysis of the US Food and Drug Administration database between 1999 and 2018.
Fan M; Chan AYL; Yan VKC; Tong X; Lau LKW; Wan EYF; Tam EYT; Ip P; Lum TY; Wong ICK; Li X
Orphanet J Rare Dis; 2022 Jan; 17(1):3. PubMed ID: 34983612
[TBL] [Abstract][Full Text] [Related]
20. Drug-review deadlines and safety problems.
Carpenter D; Zucker EJ; Avorn J
N Engl J Med; 2008 Mar; 358(13):1354-61. PubMed ID: 18367738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
